Investors Menu
Tilray Expands Medical Cannabis Footprint in Europe
-- Earns Status as Trusted Supplier of GMP-Certified Medical Cannabis to Luxembourg Ministry of Health -- -- Tilray Branded Medical Cannabis Now Available in 20 Countries Around the World -- NEW YORK --(BUSINESS WIRE)--Oct. 26, 2021-- Tilray, Inc. (“ Tilray ”) (NASDAQ | TSX: TLRY), a global pioneer
October 26, 2021
Tilray Strengthens Leadership Position in Canada
Blair MacNeil , Former Bacardi General Manager, Joins Tilray to Lead the Company’s Canadian Growth Strategy NEW YORK & LEAMINGTON, Ontario --(BUSINESS WIRE)--Oct. 19, 2021-- Tilray, Inc. (“ Tilray” or the “Company”) (NASDAQ: TLRY; TSX: TLRY) announces the expansion of its leadership team with the
October 19, 2021
Tilray, Inc. Reports First Quarter Fiscal Year 2022 Financial Results
Net Revenue and Gross Profit Increased 43% and 46%, Respectively, for Largest Global Cannabis Cultivator 10 th Consecutive Quarter of Positive Adjusted EBITDA $55 Million in Cost-Savings Achieved On a Run-Rate Basis To Date; On-track for at Least $80 Million in Cost-Savings from Aphria and Tilray
October 7, 2021
Tilray to Announce First Quarter Fiscal 2022 Financial Results on October 7, 2021
NEW YORK & LEAMINGTON, Ontario --(BUSINESS WIRE)--Sep. 23, 2021-- Tilray, Inc. (“ Tilray” or the “Company”) (NASDAQ: TLRY; TSX: TLRY) announced that the Company will release financial results for its first quarter fiscal 2022 ended August 31, 2021 before financial markets open on Thursday, October
September 23, 2021
Tilray Acquires Majority Position in Amended MedMen Convertible Notes
Investment Provides Tilray a Potential Accelerated Path into U.S. Cannabis Market Upon Federal Legalization Amendment and Extension of Convertible Notes Enables MedMen to Reshape Balance Sheet and Further Accelerate its Growth Trajectory Tilray and MedMen CEOs to Host a Conference Call and Webcast
August 17, 2021